#SmoothMuscleCell Progerin transgene drives #EndMT #Atherosclerosis🐭
⏫Aortic Endothelial Cell permeability
⏫Lesional EC infiltr▶️ColIV- & TGFβ1-rich plaque😮
Paracrine of progeroid aortic SMC?😆
#CircAHA 2024
www.ahajournals.org/doi/10.1161/...
#SmoothMuscleCell Progerin transgene drives #EndMT #Atherosclerosis🐭
⏫Aortic Endothelial Cell permeability
⏫Lesional EC infiltr▶️ColIV- & TGFβ1-rich plaque😮
Paracrine of progeroid aortic SMC?😆
#CircAHA 2024
www.ahajournals.org/doi/10.1161/...
#BranchedChainAminoAcid Catabolism
#HeartFailure
Prox1+ #LymphaticEndothelialCell BCKDK (kinase ⏬BCAA degradation) KO➡️
⏫Lymphangiogenesis
⏫Diastolic function
🐭HFpEF (L-NAME+HFD 12 wk)
Src-VEGFR3 axis
#CircAHA 2025 @ahajournals.bsky.social
www.ahajournals.org/doi/full/10....
#BranchedChainAminoAcid Catabolism
#HeartFailure
Prox1+ #LymphaticEndothelialCell BCKDK (kinase ⏬BCAA degradation) KO➡️
⏫Lymphangiogenesis
⏫Diastolic function
🐭HFpEF (L-NAME+HFD 12 wk)
Src-VEGFR3 axis
#CircAHA 2025 @ahajournals.bsky.social
www.ahajournals.org/doi/full/10....
Second heart field▶️Isl1-Dre::Myh11-RSR-CreER
Cardiac neural crest▶️Wnt1-Dre
Somite▶️Meox1-DreER
Mesothelial/Visceral▶️Upk3b-Dre
Bin Zhou lab @CircAHA 2025
www.ahajournals.org/doi/10.1161/...
Second heart field▶️Isl1-Dre::Myh11-RSR-CreER
Cardiac neural crest▶️Wnt1-Dre
Somite▶️Meox1-DreER
Mesothelial/Visceral▶️Upk3b-Dre
Bin Zhou lab @CircAHA 2025
www.ahajournals.org/doi/10.1161/...
Integrative re-analysis of GTEx bulk RNAseq, snRNAseq, metabolomics
#CircAHA 2025 @ahajournals.bsky.social
www.ahajournals.org/doi/10.1161/...
Integrative re-analysis of GTEx bulk RNAseq, snRNAseq, metabolomics
#CircAHA 2025 @ahajournals.bsky.social
www.ahajournals.org/doi/10.1161/...
AAV9-hpCas13d/gRNA
⏬30% RQ mutant mRNA
Partially rescue cardiac hypercontractility, LV hypertrophy & cardiomyocyte loss in early onset HCM of 2-mo Myh6 p.R872H/p.R404Q🐭
Resolve multiple🧍MYH7 variants
#CircAHA 2024
www.ahajournals.org/doi/10.1161/...
AAV9-hpCas13d/gRNA
⏬30% RQ mutant mRNA
Partially rescue cardiac hypercontractility, LV hypertrophy & cardiomyocyte loss in early onset HCM of 2-mo Myh6 p.R872H/p.R404Q🐭
Resolve multiple🧍MYH7 variants
#CircAHA 2024
www.ahajournals.org/doi/10.1161/...
Learn more about seamlessly transferring your manuscript between @NEJM and @CircAHA #AHA25
https://www.ahajournals.org/circ/nejm-circulation-collaboration
Learn more about seamlessly transferring your manuscript between @NEJM and @CircAHA #AHA25
https://www.ahajournals.org/circ/nejm-circulation-collaboration
#SmoothMuscleCell
1⃣H2A.Z
⬇️in #Atherosclerosis
⏫SMC contractile gene
#CircAHA 2018
www.ahajournals.org/doi/10.1161/...
#BMCGenom 2025
bmcgenomics.biomedcentral.com/articles/10....
2⃣H3.3B
⬆️in #AorticDissection
⏫SMC synthetic genes
#Genomics 2023
www.sciencedirect.com/science/arti...
#SmoothMuscleCell
1⃣H2A.Z
⬇️in #Atherosclerosis
⏫SMC contractile gene
#CircAHA 2018
www.ahajournals.org/doi/10.1161/...
#BMCGenom 2025
bmcgenomics.biomedcentral.com/articles/10....
2⃣H3.3B
⬆️in #AorticDissection
⏫SMC synthetic genes
#Genomics 2023
www.sciencedirect.com/science/arti...
Endothelial Cell Cycle
#ArterioVenousMalformation
#HereditaryHemorrhagicTelangiectasia
Evidence from
👉Fucci2🐭 (fluorescent cell cycle reporter) Retina +BMP9/10 blocking Ab
+Palbociclib CDK4/6i
👉🐭EC ALK1 KO👁️🧠
+Palbociclib
👉👤HHT2 Skin biopsy
#CircAHA 2024
www.ahajournals.org/doi/full/10....
Endothelial Cell Cycle
#ArterioVenousMalformation
#HereditaryHemorrhagicTelangiectasia
Evidence from
👉Fucci2🐭 (fluorescent cell cycle reporter) Retina +BMP9/10 blocking Ab
+Palbociclib CDK4/6i
👉🐭EC ALK1 KO👁️🧠
+Palbociclib
👉👤HHT2 Skin biopsy
#CircAHA 2024
www.ahajournals.org/doi/full/10....
TET2 #DNADemethylase #MethylcytosineDioxygenase, an epigenomic defender of #SmoothMuscleCell contractile phenotype
⏬Interferon IFNγ in SMC
Ascorbic acid
⏫TET2 activity
⏬🐭aortic #GraftArteriopathy
#CircAHA 2021 @ahajournals.bsky.social
www.ahajournals.org/doi/10.1161/...
TET2 #DNADemethylase #MethylcytosineDioxygenase, an epigenomic defender of #SmoothMuscleCell contractile phenotype
⏬Interferon IFNγ in SMC
Ascorbic acid
⏫TET2 activity
⏬🐭aortic #GraftArteriopathy
#CircAHA 2021 @ahajournals.bsky.social
www.ahajournals.org/doi/10.1161/...
Glucosamine i.p. ⏫Reperfusion #Angiogenesis but not #Arteriogenesis in🐭#LimbIschemia (BALB/c, eNOS-/- C57BL/6)
Distinct pathways from VEGFA
ATF4 as a signaling mediator
#CircAHA 2024
www.ahajournals.org/doi/10.1161/...
Glucosamine i.p. ⏫Reperfusion #Angiogenesis but not #Arteriogenesis in🐭#LimbIschemia (BALB/c, eNOS-/- C57BL/6)
Distinct pathways from VEGFA
ATF4 as a signaling mediator
#CircAHA 2024
www.ahajournals.org/doi/10.1161/...
Publishing Without Perishing: A Discussion With Leading Journal Editors
Friday, Nov 15 @ 3-4pm CT
Room: S105ABC
Program link: eppro01.ativ.me/appinfo.php?...
Publishing Without Perishing: A Discussion With Leading Journal Editors
Friday, Nov 15 @ 3-4pm CT
Room: S105ABC
Program link: eppro01.ativ.me/appinfo.php?...
Learn more about seamlessly transferring your manuscript between @NEJM and @CircAHA #ACC26
https://www.ahajournals.org/circ/nejm-circulation-collaboration
Learn more about seamlessly transferring your manuscript between @NEJM and @CircAHA #ACC26
https://www.ahajournals.org/circ/nejm-circulation-collaboration
tinyurl.com/3tttvaye
tinyurl.com/3tttvaye
@CircAHA
@AHAjournals.bsky.social
#Afghanistan faces a #health crisis: low life expectancy, few cardiologists, high #CVD ☠️ & political/economic forces that disproportionately impact women
Read about challenges our Afghan colleagues face
https://www.ahajournals.org/doi/10.1161/CIRCU…
@CircAHA
@AHAjournals.bsky.social
#Afghanistan faces a #health crisis: low life expectancy, few cardiologists, high #CVD ☠️ & political/economic forces that disproportionately impact women
Read about challenges our Afghan colleagues face
https://www.ahajournals.org/doi/10.1161/CIRCU…
CLEAR Outcomes trial post-hoc
Bempedoic acid reduces Major Adverse Cardiovascular Events & Major Adverse Limb Events
In 1624 with baseline PAD, 282 MALEs in 41 mo f/up
Absolute risk reduction 2.5% 8.3%➡️5.8%
♂️♀️?🤓
#CircAHA 2026
www.ahajournals.org/doi/10.1161/...
CLEAR Outcomes trial post-hoc
Bempedoic acid reduces Major Adverse Cardiovascular Events & Major Adverse Limb Events
In 1624 with baseline PAD, 282 MALEs in 41 mo f/up
Absolute risk reduction 2.5% 8.3%➡️5.8%
♂️♀️?🤓
#CircAHA 2026
www.ahajournals.org/doi/10.1161/...
Collab with Lulu Ren (former @mcipucd.bsky.social) & Joe Wu's Lab
@ucdavis.bsky.social
www.ahajournals.org/doi/10.1161/...
Collab with Lulu Ren (former @mcipucd.bsky.social) & Joe Wu's Lab
@ucdavis.bsky.social
www.ahajournals.org/doi/10.1161/...
#Aorta #InferiorVenaCava
CDH5-DreER::Ki67-CrexER::R26-GFP🐭
In 8-wk🐭, 8% aortic EC are proliferative over 12-wk period
⏬in YAP1 KO or VEGFR2 KO
#Piezo1 maintains aortic EC division orientation
#CircAHA 2024
www.ahajournals.org/doi/10.1161/...
#Aorta #InferiorVenaCava
CDH5-DreER::Ki67-CrexER::R26-GFP🐭
In 8-wk🐭, 8% aortic EC are proliferative over 12-wk period
⏬in YAP1 KO or VEGFR2 KO
#Piezo1 maintains aortic EC division orientation
#CircAHA 2024
www.ahajournals.org/doi/10.1161/...
🚨 HCM isn’t just driven by rare Mendelian mutations. This study highlights the role of intermediate-effect variants (IEVs)—variants with moderate effect & low penetrance—in shaping disease expression. #HCM #SoMeEditor
tinyurl.com/HCM-IEVs
🚨 HCM isn’t just driven by rare Mendelian mutations. This study highlights the role of intermediate-effect variants (IEVs)—variants with moderate effect & low penetrance—in shaping disease expression. #HCM #SoMeEditor
tinyurl.com/HCM-IEVs
Multiomics: scRNAsq, 242-CD Flow cytometry, proteomics😎
#CircAHA 2023
www.ahajournals.org/doi/10.1161/...
Multiomics: scRNAsq, 242-CD Flow cytometry, proteomics😎
#CircAHA 2023
www.ahajournals.org/doi/10.1161/...
Cell type specificity⬅️gRNA targeting cardiac-specific cis elements
#CircAHA 2024
www.ahajournals.org/doi/10.1161/...
Cell type specificity⬅️gRNA targeting cardiac-specific cis elements
#CircAHA 2024
www.ahajournals.org/doi/10.1161/...
Learn more about seamlessly transferring your manuscript between @nejm.org and #CircAHA
https://www.ahajournals.org/circ/nejm-circulation-collaboration
#TCT2025
Learn more about seamlessly transferring your manuscript between @nejm.org and #CircAHA
https://www.ahajournals.org/circ/nejm-circulation-collaboration
#TCT2025
Learn more about seamlessly transferring your manuscript between @nejm.org and #CircAHA
https://www.ahajournals.org/circ/nejm-circulation-collaboration
#TCT2025
Learn more about seamlessly transferring your manuscript between @nejm.org and #CircAHA
https://www.ahajournals.org/circ/nejm-circulation-collaboration
#TCT2025